Fig. 2
From: MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
The association of MAPK8IP2 expression with clinicopathological factors in PCa (TCGA database). A-F MAPK8IP2 expression levels were significantly associated with PSA (A), Gleason score (B), primary therapy outcome (C), T stage (D), N stage (E), and residual tumor (F). G, H Kaplan–Meier analysis was performed to estimate the PFI (G) and OS (H) between the low and high MAPK8IP2 expression groups. I ROC curves were used to assess the predictive ability of MAPK8IP2 for PCa. CR: complete response; PD: progressive disease; SD: stable disease; PR: partial response; PFI: progression-free interval; OS: overall survival; ROC: receiver operating characteristic; *p < 0.05, **p < 0.01, ***p < 0.001